Lee Ainslie Arvinas, Inc. Transaction History

Maverick Capital LTD

  • $5.08 Billion
  • Q1 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$26.15 - $37.26 $124,526 - $177,432
4,762 Added 40.17%
16,618 $454,000
Q4 2022

Feb 14, 2023
BUY
$32.47 - $57.24 $123,256 - $217,283
3,796 Added 47.1%
11,856 $405,000
Q3 2022

Nov 14, 2022
BUY
$41.87 - $57.99 $337,472 - $467,399
8,060 New
8,060 $359,000

Others Institutions Holding ARVN

# of Institutions
246
Shares Held
62.5M
Call Options Held
2.65M
Put Options Held
1.1M
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $346M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email